miR-491-5p functions as a tumor suppressor by targeting IGF2 in colorectal cancer

Lei Lu*  
Ming Cai*  
Meixia Peng  
Fei Wang  
Xiaofeng Zhai  
Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu, China  
*These authors contributed equally to this work

Background: Dysregulation of miRNAs is critically implicated in tumorigenesis, and aberrant expression of miR-491-5p has been reported to play a key role in initiation and progression of various cancers. However, the biological function and underlying mechanism of miR-491-5p in colorectal cancer (CRC) remain elusive.

Methods: Quantitative real-time PCR (qRT-PCR) was employed to evaluate the levels of miR-491-5p and IGF2 mRNA expression in CRC tissues, cell lines and plasma. Cell counting kit-8 and colony formation assays were used to detect the effects of miR-491-5p on CRC cell growth. Luciferase reporter assays were applied to confirm the miR-491-5p target gene. In vivo experiments were conducted in nude mice.

Results: miR-491-5p was found to be obviously downregulated in CRC tissues and cell lines, and decreased miR-491-5p expression level was shown to be associated with differentiation, TNM stage and poor overall survival (OS). miR-491-5p overexpression suppressed CRC cell proliferation both in vitro and in vivo. Mechanically, insulin-like growth factor 2 (IGF2) was identified to be a direct target of miR-491-5p in CRC cells, and overexpression of IGF2 rescued the miR-491-5p-induced suppression of proliferation in CRC cells. Finally, we demonstrated that plasma miR-491-5p expression was decreased in CRC when compared to healthy controls and might be an effective diagnostic biomarker for CRC.

Conclusion: These data showed that miR-491-5p functioned as a tumor suppressor by targeting IGF2 in CRC, and miR-491-5p could serve as a potential diagnostic and prognostic biomarker for CRC.

Keywords: miR-491-5p, IGF2, colorectal cancer, proliferation, biomarker

Introduction

Colorectal cancer (CRC) is one of the most common cancers and a leading cause of death worldwide.1 Despite great improvement in cancer diagnosis and treatment, the 5-year overall survival (OS) rate remains unsatisfied. Therefore, elucidation of the mechanism underlying CRC progression is urgently required.

miRNAs, a class of short noncoding RNAs, inversely regulate the expression of target genes via translational repression or elevating mRNA degradation.2-3 Mounting evidence indicated that many miRNAs were differently expressed in various cancers and play key roles in numerous biological processes, including cell growth, apoptosis, migration, invasion, metastasis and so on.4-6 miR-491-5p, located on chromosome 9p21.3, has been found to be dysregulated and function as a tumor suppressor in various cancers. Hui et al reported that miR-491-5p functioned as a tumor suppressor by...
targeting JMJD2B in ERα-positive breast cancer. Sun et al\(^8\) reported that Foxi1-mediated miR-491-5p inhibited the development of gastric cancer via suppressing Wnt3α/β-catenin signaling. However, the role of miR-491-5p in the progression and development of CRC remains unclear.

Insulin-like growth factor 2 (IGF2), a 7.5 kDa peptide produced by liver and many tissues, has been reported to be closely associated with many cancers.\(^9\) Li et al\(^10\) reported that miR-223 was upregulated by MYOD and inhibited myoblast proliferation by repressing IGF2. Yang et al\(^11\) reported that miR-615-5p targeted IGF2 and functioned as a tumor suppressor in esophageal squamous cell carcinoma (ESCC).

In this study, we aimed to explore the role of miR-491-5p in development and progression of CRC and its potential value of prognosis and diagnosis in CRC. miR-491-5p was found to be downregulated in CRC tissues and cell lines compared with adjacent normal tissues (ANTS) and colonic mucosal epithelial cell line (FHC), respectively. Moreover, we also detected that miR-491-5p expression level was significantly correlated with differentiation and TNM stage. Additionally, we found that miR-491-5p inhibited tumor cell growth in vitro and in vivo, whereas IGF2 could abrogate the inhibitory effect caused by miR-491-5p in CRC.

**Materials and methods**

**Patients and tissue specimens**

Eighty pairs of CRC and ANTs were obtained from CRC patients who underwent surgery at the Second Affiliated Hospital of Nantong University. The patients who received system treatments were excluded. The CRC tissues were frozen in liquid nitrogen after surgical resection and stored at \(-80°C\) until RNA extraction. Written informed consents were obtained from all these patients, and this procedure was conducted in accordance with the Declaration of Helsinki. This study was approved by the institutional review board of the Second Affiliated Hospital of Nantong University. Clinopathological characteristics of these patients are listed in Table 1.

---

**Table 1** Correlation between miR-491-5p expression and different clinical characteristics

| Characteristics          | No of patients (%) (n=80) | miR-491-5p expression | P-value |
|--------------------------|---------------------------|-----------------------|---------|
|                          |                           | Low, n (%) (n=40)     | High, n (%) (n=40) |
| Age (years)              |                           |                       |         |
| <60                      | 29 (36.3)                 | 17 (42.5)             | 12 (30.0) |
| ≥60                      | 51 (63.7)                 | 23 (57.5)             | 28 (70.0) |
| Gender                   |                           |                       |         |
| Female                   | 37 (46.3)                 | 16 (40.0)             | 21 (52.5) |
| Male                     | 43 (53.7)                 | 24 (60.0)             | 19 (47.5) |
| Tumor location           |                           |                       |         |
| Colon                    | 45 (56.3)                 | 25 (62.5)             | 20 (50.0) |
| Rectum                   | 35 (43.7)                 | 15 (37.5)             | 20 (50.0) |
| Tumor size (cm)          |                           |                       |         |
| <5                       | 33 (41.3)                 | 15 (37.5)             | 18 (45.0) |
| ≥5                       | 47 (58.7)                 | 25 (62.5)             | 22 (55.0) |
| Differentiation          |                           |                       |         |
| Well                     | 8 (10.0)                  | 4 (10.0)              | 4 (10.0) |
| Moderate                 | 51 (63.8)                 | 19 (47.5)             | 32 (80.0) |
| Poor                     | 21 (26.2)                 | 17 (42.5)             | 4 (10.0) |
| Serum CEA level (ng/mL)  |                           |                       |         |
| <10                      | 33 (41.3)                 | 18 (45.0)             | 15 (37.5) |
| ≥10                      | 47 (58.7)                 | 22 (55.0)             | 25 (62.5) |
| Local invasion           |                           |                       |         |
| T1–T2                    | 14 (17.5)                 | 6 (15.0)              | 8 (20.0) |
| T3–T4                    | 66 (82.5)                 | 34 (85.0)             | 32 (80.0) |
| Lymph node metastasis    |                           |                       |         |
| N0–N1                    | 46 (57.5)                 | 21 (52.5)             | 25 (62.5) |
| N2                       | 34 (42.5)                 | 19 (47.5)             | 15 (37.5) |
| TNM stage                |                           |                       |         |
| I–II                     | 44 (55.0)                 | 12 (30.0)             | 32 (80.0) |
| III–IV                   | 36 (45.0)                 | 28 (70.0)             | 8 (20.0) |

Abbreviation: CEA, carcinoembryonic antigen.
Cell culture and transfection
Five human CRC cell lines (HCT116, HCT8, HT29, SW620 and SW480) and colonic mucosal epithelial cell line (FHC) were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in DMEM (KeyGen BioTECH, Nanjing, China) containing 10% FBS (HyClone™; Thermo Fisher Scientific, Waltham, MA, USA) at 37°C supplemented with 5% CO₂.

Cell transfection
For transfection, 2×10⁵ HCT116 and HCT8 cells were seeded into six-well plates and transiently transfected with 20 nM of agomiR-491-5p, antagomiR-491-5p (GenePharma, Shanghai, China) and pcDNA3.1-IGF2 or agomiR-NC, antagomiR-NC and blank vector (vector) using Lipofectamine™ 2000 (Thermo Fisher Scientific) in accordance with the manufacturer’s protocol.

Quantitative real-time PCR (qRT-PCR)
TRIzol Reagent (Thermo Fisher Scientific) was employed to extract total RNA from CRC tissues, cells and plasma following manufacturer’s instructions. Hairpin-it™ microRNA and U6 snRNA normalization RT-PCR quantitation kit (GenePharma) were employed to detect miR-491-5p expression levels. The IGF2 mRNA levels were assessed using PrimeScript RT reagent Kit and SYBR Premix Ex Taq (Takara, Dalian, China). All results were normalized to U6, GAPDH, and Caenorhabditis elegans miR-39 (cel-miR-39) was employed as internal control for plasma samples. The relative expression of miR-491-5p or IGF2 mRNA was quantified using the 2–ΔΔCt method.

Western blot
Cells were lysed using lysis buffer (KeyGen BioTECH) supplemented with protease inhibitors, phosphatase inhibitor and phenylmethanesulfonil fluoride (PMSF). Then, protein was separated using 10% SDS-PAGE gel and transferred to polyvinylidene difluoride (PVDF) membranes (EMD Millipore, Billerica, MA, USA). Then, the membranes were incubated with IGF2 and GAPDH antibody (Abcam, Cambridge, UK) overnight. The membranes were then incubated with secondary antibodies after three washes. The bands were detected using an chemiluminescent (enhanced chemiluminescence [ECL]) system (EMD Millipore).

Dual luciferase reporter assay
Two hundred ninety-three T cells were seeded into 24-well plates for 24 hours, wild-type IGF2 3′-UTR (WT-IGF2 3′-UTR) or mutant IGF2 3′-UTR (Mut-IGF2 3′-UTR) was cotransfected with agomiR-491-5p or agomiR-NC using Lipofectamine™ 2000 (Thermo Fisher Scientific) in accordance with the manufacturer’s protocol. Luciferase activity was detected using Dual-Luciferase Reporter Assay System (Promega Corporation, Fitchburg, WI, USA), and Renilla luciferase was employed for normalization.

Immunohistochemical (IHC) staining assay
Five-micrometer sections of paraffin-embedded tissues were blocked at room temperature with 5% goat serum in tris buffered saline (TBS) for 0.5 hour. Then, the sections were incubated with anti-IGF2 (ab9574; Abcam) at 4°C overnight and washed with tris buffered saline with tween 20 (TBST) (3×10 minutes) before incubation with secondary antibody (Dako Cytomation, Glostrup, Denmark) for 0.5 hour at room temperature. Finally, the sections were stained using hematoxylin and visualized under an inverted microscope at 400× (Olympus Corporation, Tokyo, Japan). The intensity of staining was scored by two independent pathologists in the following four categories: no staining =0, weak staining =1, moderate staining =2 and strong staining =3. The stain-positive was scored into the following four grades: 0 (0%), 1 (1%–33%), 2 (34%–66%) and 3 (67%–100%). The final IHC score was calculated by multiplying the percentage of positive cells with the intensity score.

Cell proliferation assay
Cell counting kit-8 (CCK-8; KeyGen BioTECH) was performed to assess the cell viability in accordance with the manufacturer’s instruction. The absorbance at 450 nm was detected using a microplate reader (Bio-Tek Instruments Inc., Winooski, VT, USA).

Colony formation assay
In order to assess colony formation, 1×10⁵ cells were seeded into a six-well plate and then cultured with DMEM containing 10% FBS for 2 weeks. The colonies were fixed with methanol for 15 minutes and stained using 0.1% crystal violet (Beyotime, Shanghai, China).

In vivo experiments
All animal experiments were approved by the animal care committee of the Second Affiliated Hospital of NanTong University and were performed in accordance with the animal experimental guidelines of Nantong University. 1×10⁷ HCT116 cells were subcutaneously injected into the armpit region of 24 6-week-old male BABL/c nude mice that were divided into
four groups (n=6 each group), and after tumor formed (4 days after injection), 2 nmol miR-491-5p agomir/antagomir or its negative control (agomiR-NC/antagomiR-NC) was injected into the tumors. The tumors were measured every 5 days. The volume of tumors was calculated using the following equation: \( V = \frac{L \times W^2}{2} \), where \( L \) is the length and \( W \) is the width of tumor.

Statistical analyses

All experiments were performed more than three times. The data are shown as mean ± SD and analyzed by SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). The Student’s t-test and one-way ANOVA were employed to estimate the differences between groups. The chi-squared test or Pearson’s Mann–Whitney U-test was used to analyze the relationship between expression of miR-491-5p and clinicopathological features. The Kaplan–Meier method was performed to assess OS. The survival curves were compared with the log-rank test. Follow-up time was censored if the patient was lost to follow-up. Cox proportional hazards model was employed to perform multivariate analysis and calculate 95% CI. The area under the receiver operating characteristic (ROC) curve (AUC) was performed to assess the feasibility of plasma miR-491-5p as a potential diagnostic biomarker for CRC. Values of \( P<0.05 \) were considered to be statistically significant.

Results

miR-491-5p was downregulated in CRC tissues and cell lines

To explore the role of miR-491-5p in CRC, miR-491-5p expression was assessed using qRT-PCR in 80 pairs of CRC tissues and matched ANTs. The relative expression of miR-491-5p in CRC tissues was markedly downregulated in comparison with that in ANTs (Figure 1A). Moreover, we also found that miR-491-5p was significantly decreased in CRC cell lines compared with FHC (Figure 1B).

Low expression of miR-491-5p in CRC tissues is closely associated with poor clinicopathological features and prognosis in CRC

To further explore the clinicopathological significance of miR-491-5p levels in CRC samples, 80 CRC patients were...
divided into two groups (low and high miR-491-5p groups) with the median miR-491-5p expression levels serving as the cutoff point between the two groups. This study showed that lower levels of miR-491-5p were markedly correlated with TNM stage and differentiation \((P<0.05; Table 1)\). Taken together, our findings indicated that downregulated miR-491-5p expression was closely correlated with progression of CRC.

Next, Kaplan–Meier survival curves indicated that CRC patients with low expression of miR-491-5p showed an obviously reduced OS (Figure 1C). Moreover, a univariate analysis showed that TNM stage, differentiation and miR-491-5p were obviously associated with OS in CRC patients (Table 2). A multivariate analysis also revealed that miR-491-5p was an independent prognostic indicator for OS (Table 2).

**miR-491-5p inhibited CRC cell proliferation**

To investigate the potential role of miR-491-5p in regulating CRC cell growth, first, agomiR-491-5p was used to force miR-491-5p expression, whereas antagomiR-491-5p was employed to reduce the expression of miR-491-5p, and the efficiency of transfection was assessed using qRT-PCR (Figure 2A). Then, CCK-8 and colony formation assays were performed to observe the ability of cell proliferation. CCK-8 assay indicated that overexpression of miR-491-5p suppressed, whereas suppression of miR-491-5p promoted CRC cell proliferation in both HCT116 and HCT8 cell lines compared to the negative control group (agomiR-NC and antagomiR-NC), respectively (Figure 2B). Additionally, we also demonstrated that miR-491-5p inhibited cell proliferation in both cells using colony formation, in contrast, compared to the control group, knocking-down miR-491-5p expression could promote CRC cell proliferation in both cells (Figure 2C). The abovementioned in vitro data indicated that miR-491-5p functioned as a tumor suppressor in CRC cell lines.

**miR-491-5p suppressed tumor growth in vivo**

The cells were subcutaneously implanted into each nude mice in vivo, and the tumor volumes were measured every 5 days. Our results showed that miR-491-5p overexpression obviously repressed tumorigenesis, whereas miR-491-5p downregulation markedly promoted tumor growth (Figure 3A and B). Together, these data further demonstrated that miR-491-5p functioned as a tumor suppressor in CRC.

**IGF2 is a direct target gene of miR-491-5p**

IGF2 was selected as a potential target gene of miR-491-5p using TargetScan and miRanda algorithms, for it was reported to promote cancer progression in various cancers. To further confirm that IGF2 is a direct target gene of miR-491-5p, a dual-luciferase reporter assay was performed. Our results showed that miR-491-5p overexpression significantly reduced the luciferase activity of wild-type IGF2-3′-UTR in 293 T cells, whereas it failed to repress the mutated IGF2 3′-UTR (Figure 4A). To determine whether miR-491-5p regulated endogenous IGF2 expression in OS cell lines, mRNA and protein expression levels of IGF2 were assessed by qRT-PCR and Western blot, respectively. We found that miR-491-5p overexpression could significantly decrease the expression of IGF2 in mRNA and protein levels, whereas miR-491-5p downregulation could increase IGF2 expression levels both in mRNA and protein in CRC cells (Figure 4B and C).

| Characteristics                  | Multivariate analysis for OS | Univariate analysis for OS |
|----------------------------------|------------------------------|---------------------------|
|                                  | HR (95% CI)                  | HR (95% CI)               |
| Age (<60/≥60 years)              | –                            | 1.013 (0.781–1.312)       | 0.462 |
| Gender (female/male)             | –                            | 0.819 (0.516–1.232)       | 0.615 |
| Tumor location (colon/rectum)    | –                            | 0.718 (0.561–1.313)       | 0.551 |
| Tumor size (<5/≥5 cm)            | –                            | 0.981 (0.671–1.234)       | 0.214 |
| Differentiation (well/moderate/poor) | 1.878 (1.212–3.132)      | 3.245 (2.142–5.781)       | 0.005 |
| CEA (<10/≥10 ng/mL)              | –                            | 0.891 (0.526–1.216)       | 0.121 |
| Location invasion (T1+T2/T3+T4)  | –                            | 1.034 (0.802–1.321)       | 0.221 |
| Lymph node metastasis (N0–N1/N2) | –                            | 0.919 (0.701–1.342)       | 0.395 |
| TNM stage (i–ii/iii–iv)          | 1.742 (0.965–3.145)         | 3.342 (2.311–5.095)       | <0.001 |
| miR-491-5p (low/high)            | 0.479 (0.245–0.939)         | 0.314 (0.226–0.524)       | 0.004 |

Abbreviations: CRC, colorectal cancer; OS, overall survival.

Table 2 Univariate and multivariate analyses for OS in patients with CRC
Figure 2 miR-491-5p inhibited CRC cell proliferation in vitro. 

Notes: (A) qRT-PCR analysis of miR-491-5p expression in HCT116 and HCT8 cells after transfection of miR-491-5p agomir/antagomir or their negative control (agomiR-NC and antagomiR-NC). (B) Cell proliferation was determined in HCT116 and HCT8 cells after transfection with miR-491-5p agomir/antagomir or agomiR-NC/antagomiR-NC using CCK-8 assay. (C) Colony formation assay was performed to detect the ability of proliferation in HCT116 and HCT8 after transfection with miR-491-5p agomir/antagomir or agomiR-NC/antagomiR-NC. Data are shown as mean ± SD. *P<0.05, ***P<0.001.

Abbreviations: CCK-8, cell counting kit-8; CRC, colorectal cancer; nC, negative control; OS, overall survival; qRT-PCR, quantitative real-time PCR.
IGF2 overexpression reverses inhibitory effects of miR-491-5p in CRC

To further prove the functional connection between miR-491-5p and IGF2, we cotransfected with IGF2 expression plasmid or blank vector (vector) and agomiR-491-5p in HCT116 and HCT8 cell lines. The expression of IGF2 was markedly increased after cotransfection with agomiR-491-5p and pcDNA3.1-IGF2 (Figure 5A). Overexpression of IGF2 could partially abrogate the inhibitory effect on cell proliferation caused by agomiR-491-5p (Figure 5B and C). Based on the abovementioned results, we could conclude that miR-491-5p inhibits CRC cell growth via targeting IGF2.

The relationship between miR-491-5p and IGF2 in CRC tissues

To investigate the relationship between miR-491-5p and IGF2, we also analyzed IGF2 protein expression in CRC tissues with different miR-491-5p levels, the low vs high miR-491-5p expression was defined as the median value of miR-491-5p level according to the cohort of tested CRC patients. As shown in Figure 6A and B, the levels of IGF2 protein expression in low-miR-491-5p CRC tissues were obviously higher than those of high-miR-491-5p CRC tissues. Meanwhile, a significant negative correlation was found between IGF2 protein levels and miR-491-5p expression levels in CRC tissues (Figure 6C). Additionally, the expression of IGF2 mRNA was also elevated in CRC tissues than that in ANTs, and an inverse correlation was found between IGF2 mRNA and miR-491-5p expression levels in CRC tissues (Figure 6D and E).

miR-491-5p might be a potential diagnostic biomarker in CRC

To determine whether plasma miR-491-5p could be a screening biomarker for CRC, we compared plasma miR-491-5p levels between healthy volunteers and patients with CRC. Our data showed that plasma miR-491-5p levels in the CRC patient group were significantly lower than the levels in the healthy controls group (Figure 7A). A ROC curve was performed to construct for distinguishing healthy controls from patients with CRC. The results showed that the AUC was up to 0.810 (95% CI, 0.733–0.877; P<0.001). In the cutoff values from ROC curves shown in Figure 7B, when the cutoff value of plasma miR-491-5p was −0.205, the sensitivity was 90.0%, and the specificity was 67.5%.
Figure 4 IGF2 is a direct target gene of miR-491-5p.

Notes: (A) The luciferase activity was measured after cotransfecting with WT/Mut IGF2 3'-UTR plasmid and agomiR-491-5p/agomiR-NC in 293 T cells. qRT-PCR (B) and Western blot (C) analyses were performed to detect the expression of IGF2 in HCT116 and HCT8 after transfection with agomiR-491-5p and antagomiR-491-5p or agomiR-NC and antagomiR-NC. Data are shown as mean ± SD of three independent experiments. *P<0.05, **P<0.01, and ***P<0.001.

Abbreviations: Mut, mutant; NC, negative control; qRT-PCR, quantitative real-time PCR; WT, wild type.
Figure 5 Overexpression of IGF2 reverses the effects induced by miR-491-5p overexpression in HCT116 and HCT8 cells. 

Notes: (A) IGF2 protein expression was detected in HCT116 and HCT8 cells cotransfected with agomiR-491-5p and IGF2 expression plasmid or blank vector (vector). (B and C) Cell proliferation was determined in HCT116 and HCT8 cells cotransfected with agomiR-491-5p and IGF2 expression plasmid or blank vector (vector). Data are shown as mean ± SD of three independent experiments. *P<0.05, **P<0.01, and ***P<0.001.
Figure 6 The relationship between miR-491-5p and IGF2 in CRC tissues.

Notes: (A) Representative IHC staining (×200) for IGF2 from CRC tissues and matched ANTs. (B) IHC scores of IGF2 in low miR-491-5p CRC tissues were markedly higher than those in high miR-491-5p CRC tissues. (C) The correlation between the levels of miR-491-5p expression and IHC scores of IGF2 in CRC tissues. (D) qRT-PCR was employed to measure the expression of IGF2 mRNA in 80 CRC specimens and corresponding ANTs. (E) The correlation analysis was performed between IGF2 mRNA and miR-491-5p expression levels. Data are shown as mean ± SD. ***P<0.001.

Abbreviations: ANTs, adjacent normal tissues; CRC, colorectal cancer; IHC, immunohistochemical; NC, negative control; qRT-PCR, quantitative real-time PCR.

Figure 7 Plasma levels of miR-491-5p were downregulated in CRC patients.

Notes: (A) The relative levels of miR-491-5p in patients with CRC and healthy controls. The data are shown as log_{10} and normalized to cel-miR-39. (B) ROC curves for miR-491-5p in 80 CRC patients and 40 healthy controls. Data are shown as mean ± SD. ***P<0.001.

Abbreviations: CRC, colorectal cancer; ROC, receiver operating characteristic.
Discussion

Accumulating studies showed that abnormally expressed miRNAs promoted or suppressed tumor development and progression, including CRC.\textsuperscript{12,13} Cao et al\textsuperscript{14} reported that miR-381 was increased in gastric cancer tissues and cells, and downregulation of miR-381 was correlated with adverse clinicopathological features and poor prognosis. Liu et al\textsuperscript{15} reported that miR-29c was downregulated in lung adenocarcinoma (LAD), and downregulated miR-29c was found to be poor prognosis in IIIA-N2 LAD. In this study, we found that miR-491-5p was markedly downregulated in CRC tissues and cell lines. Moreover, we found that low expression of miR-491-5p was closely associated with TNM stage and differentiation. These data preliminary showed that miRNAs functioned as a tumor suppressor in CRC.

Xu et al\textsuperscript{16} reported that miR-491-5p inhibited cell proliferation and migration by targeting platelet-derived growth factor receptor \(\alpha\) (PDGFRA). Hui et al\textsuperscript{17} reported that miR-491-5p was obviously decreased in ER\(\alpha\)-positive breast cancer tissues and cell lines, and overexpression of miR-491-5p inhibited breast cancer cell proliferation via induction of cell cycle G1 arrest by targeting JMJD2B. Here, to further explore biological function of miR-491-5p in CRC, in vitro and in vivo experiments were performed. Our results showed that overexpression of miR-491-5p could significantly inhibit CRC cell growth, whereas downregulation of miR-491-5p could markedly promote CRC cell growth, which was verified using CCK-8, colony formation and subcutaneous tumor growth assays.

It is well accepted that miRNAs exert their function primarily based on their target genes.\textsuperscript{18–20} To investigate the potential mechanism of miR-491-5p in CRC progression, bioinformatics analysis was employed to identify potential target gene of miR-491-5p, and IGF2 was selected as a putative miR-491-5p target gene. Yang et al\textsuperscript{21} observed that the inhibitory effects of miR-615-5p on ESCC cell mobility were partially abrogated by the upregulation of IGF2 expression. Gebeshuber et al\textsuperscript{22} revealed that miR-100 is a regulator of the IGF2/mTOR signaling pathway and a promising target for therapeutic approaches in breast. Next, we confirmed that IGF2 was a direct target gene of miR-491-5p using a luciferase reporter assay. miR-491-5p overexpression could significantly reduce IGF2 expression both on protein and mRNA levels. Moreover, we found that IGF2 upregulation could reverse the tumor-suppressive effects of miR-491-5p on CRC cells. Collectively, our findings revealed that miR-491-5p exerted its antitumor effect on CRC cells by targeting IGF2.

Luo et al\textsuperscript{23} reported that miRNAs play key roles in oncogenesis, and the dysregulated expression of miRNAs might be indicative of the presence of CRC. In this study, we tested the diagnostic value of plasma miR-491-5p in differentiating people without CRC from patients with CRC. We observed that plasma miR-491-5p levels from CRC patients were obviously lower than those from healthy controls. These results revealed that plasma miR-491-5p had a potential diagnostic value in CRC.

Conclusion

This study showed that miR-491-5p was downregulated in CRC tissues and cells. Moreover, low miR-491-5p expression was closely associated with the differentiation, TNM stage and poor OS. Moreover, we demonstrated that miR-491-5p inhibited CRC cell growth by targeting IGF2. Finally, we found that the expression of plasma miR-491-5p was decreased in CRC patients in comparison with that in healthy controls. These data may imply that miR-491-5p might be a potential biomarker and therapeutic target for CRC.

Acknowledgment

Lei Lu and Ming Cai are co-first authors for this study.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Siegel R, Naishadham D, Jemal A, Statistics C. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
2. Bagga S, Bracht J, Hunter S, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell. 2005;122(4):553–563.
3. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233.
4. White NM, Mendell JT. MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther. 2008;7(12):3655–3660.
5. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94(6):776–780.
6. Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther. 2008;7(12):3655–3660.
7. Hui Z, Yiling C, Wenting Y, Xuqun H, Chuanyi Z, Hui L. miR-491-5p functions as a tumor suppressor by targeting Wnt3a/\(\beta\)-catenin signaling in the development of gastric cancer. Cell Death Dis. 2017;8(3):e3094.
8. Sun R, Liu Z, Tong D, et al. miR-491-5p, mediated by Foxi1, functions as a tumor suppressor by targeting JMD2B in ER\(\alpha\)-positive breast cancer. FEBS Lett. 2015;589(7):812–821.
9. Li G, Luo W, Abdalla BA, et al. miRNA-223 upregulated by MYOD inhibits myoblast proliferation by repressing IGF2 and facilitates myoblast differentiation by inhibiting ZEB1. Cell Death Dis. 2017;8(10):e3094.
10. Yang B, Xie R, Wu SN, Gao CC, Yang XZ, Zhou JF. MicroRNA-615-5p targets insulin-like growth factor 2 and exerts tumor-suppressing functions in human esophageal squamous cell carcinoma. Oncol Rep. 2018;39(1):255–263.
11. Hua KT, Hong JB, Sheen YS, et al. miR-519d promotes melanoma progression by downregulating EphA4. Cancer Res. 2018;78(1):216–229.
13. Zhao HJ, Ren LL, Wang ZH, et al. MiR-194 deregulation contributes to colorectal carcinogenesis via targeting AKT2 pathway. Theranostics. 2014;4(12):1193–1208.
14. Cao Q, Liu F, Ji K, et al. MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TME61A expression. J Exp Clin Cancer Res. 2017;36(1):29.
15. Liu L, Bi N, Wu L, et al. MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma. Mol Cancer. 2017;16(1):50.
16. Xu Y, Hou R, Lu Q, et al. MiR-491-5p negatively regulates cell proliferation and motility by targeting PDGFRα in prostate cancer. Am J Cancer Res. 2017;7(12):2545–2553.
17. Hui Z, Yiling C, Wenting Y, Xuqun H, Chuanyi Z, Hui L. miR-491-5p functions as a tumor suppressor by targeting JMD2B in ERα-positive breast cancer. FEBS Lett. 2015;589(7):812–821.
18. Farazi TA, Spitzer JI, Morozov P, Tuschi T. miRNAs in human cancer. J Pathol. 2011;223(2):102–115.
19. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835–840.
20. Mcmanus MT. MicroRNAs and cancer. Semin Cancer Biol. 2003;13(4):253–258.
21. Yang B, Xie R, Wu SN, Gao CC, Yang XZ, Zhou JF. MicroRNA-615-5p targets insulin-like growth factor 2 and exerts tumor-suppressing functions in human esophageal squamous cell carcinoma. Oncol Rep. 2018;39(1):255–263.
22. Gegebush CA, Martinez J. miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. Oncogene. 2013;32(27):3306–3310.
23. Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol Biomarkers & Prev. 2011;20(7):1272–1286.